Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa

Дата публикации: 08-07-2026 16:18:48

GLP-1 receptor agonist therapy was associated with lower all-cause mortality among people with hidradenitis suppurativa — a benefit that lasted up to 2 years, according to a study published in JAMA Dermatology.These findings were consistent even among patients without diabetes who had HS, according to Beata Jastrząb-Miśkiewicz, MD, PhD, a dermatologist, venereologist and lead investigator of the study.“It suggests that the association between GLP-1 receptor agonists and improved HS outcomes may not be explained only by better glycemic control,” Jastrząb-Miśkiewicz told Healio. “It raises

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1GLP-1s may improve outcomes in patients with PAD, diabetes5708-07-2026
2Most websites prescribe GLP-1s without clinician visit0709-07-2026
3Combination GLP-1 and SGLT2 therapy may lower heart risk0525-06-2026
4Decoding the evidence on peptides, from topicals to longevity2609-07-2026
5Doctors' fears over long-term Ozempic use: DR SHEILA sounds the alarm over GLP-1 weight-loss drugs for young patients-2627-06-2026
6Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity7831-07-2025
7Women more often hired after losing weight on GLP-1s: Study0.20.603-07-2026
8Will GLP-1s lead to fewer prescriptions for older adults?0725-06-2026
9Weight-loss jab users more likely to report changes in taste and smell, study finds0729-06-2026
10Weight Loss at a Cost—Sense and Sensibility0725-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: www.healio.com.